<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363039">
  <stage>Registered</stage>
  <submitdate>17/09/2012</submitdate>
  <approvaldate>9/10/2012</approvaldate>
  <actrnumber>ACTRN12612001077853</actrnumber>
  <trial_identification>
    <studytitle>The effect of critical illness on fat absorption: comparative measurements in healthy volunteers</studytitle>
    <scientifictitle>The effect of critical illness on enteral absorption of long chain triglycerides: comparative measurements in healthy volunteers</scientifictitle>
    <utrn>U1111-1134-5631</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Critical illness</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A 60ml Intraduodenal infusion at 120ml/hr of liquid nutrient mixed with 13C-triolein and 3-OMG infused into healthy volunteers</interventions>
    <comparator>The control group consists of healthy volunteers. This group is age and sex matched with critically ill patients who have previously been studied by the investigators using the same method between 2010 and 2011.</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome will be lipid absorption in the healthy population, which can then be compared to the data that the investigators have already obtained in the critically ill, mechanically ventilated population.
Lipid absorption is derived from end-expiratory breath samples (10mL) for the measurement of the 13C-Triolein by-product, 13CO2, which will be taken throughout the study.</outcome>
      <timepoint>At baseline, 5, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 minutes after the commencement of the infusion.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Glucose absorption as derived from the area under the 3-OMG concentration curve, peak concentration and time to peak. This will be measured from venous blood samples(5ml).</outcome>
      <timepoint>At baseline, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and 360 minutes after the commencement of the infusion.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration of motilin measured from venous blood samples (4ml).</outcome>
      <timepoint>At baseline, 30 and 240 minutes after the commencement of the infusion.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers aged over 17 years.</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Inability to give informed consent.
Contraindication to naso-duodenal feeding tube placement.
Previous surgery on the oesophagus, stomach or duodenum.
Any gastrointestinal disease.
History of diabetes mellitus.
Pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>5/09/2012</anticipatedstartdate>
    <actualstartdate>5/09/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/01/2014</actualenddate>
    <samplesize>15</samplesize>
    <actualsamplesize>16</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/01/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <postcode>5000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Yasmine Ali Abdelhamid</primarysponsorname>
    <primarysponsoraddress>Intensive Care Unit
Royal Adelaide Hospital
North Terrace
Adelaide
SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to understand how healthy people absorb glucose (sugar) and lipids (fat) from their small intestine. This information can then be compared to information we are collecting about nutrient absorption in Intensive Care Unit patients. We hypothesize that absorption will be reduced in Intensive Care Unit patients compared to healthy volunteers.</summary>
    <trialwebsite />
    <publication>Ali Abdelhamid Y, Cousins CE, Sim JA, Bellon MS, Nguyen NQ, Horowitz M, Chapman MJ, Deane AM. Effect of Criticall Illness on Triglyceride Absorption. JPEN J Parenter Enteral Nutr. 2015 Nov;39(8):966-72. doi: 10.1177/0148607114540214. Epub 2014 Jun 24.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Royal Adelaide Hospital North Terrace, Adelaide, South Australia 5000</ethicaddress>
      <ethicapprovaldate>21/12/2011</ethicapprovaldate>
      <hrec>111217</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Yasmine Ali Abdelhamid</name>
      <address>Intensive Care Unit
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61882224624</phone>
      <fax />
      <email>yasmine.aliabdelhamid@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Yasmine Ali Abdelhamid</name>
      <address>Intensive Care Unit
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61882224624</phone>
      <fax />
      <email>yasmine.aliabdelhamid@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Yasmine Ali Abdelhamid</name>
      <address>Intensive Care Unit
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61882224624</phone>
      <fax />
      <email>yasmine.aliabdelhamid@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yasmine Ali Abdelhamid</name>
      <address>ICU Research Department,
Royal Adelaide Hospital,
North Terrace, Adelaide, South Australia, 5000
Australia</address>
      <phone>+61 8 8222 4624</phone>
      <fax />
      <email>yasmine.aliabdelhamid@sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>